The Talc Settlement Participation Threshold Is Now on a Two-Week Clock in MDL 2738

The talc settlement participation threshold — the 95% sign-up condition Johnson & Johnson attached to its $5.5 billion ovarian talc deal on 27 July 2026 — is now being counted in public, on a fortnightly schedule, in the largest Multidistrict Litigation (MDL) in the federal system. The District of New Jersey has held the deadlines in MDL No. 2738 in abeyance and directed Negotiation Counsel to file updates on claimant communications, claimant participation and the settlement process beginning 15 September 2026 and every two weeks thereafter until otherwise ordered, which means 69,250 pending federal actions are now waiting on a number that appears in a status report rather than in a judgment.

That is an unusual posture for a Mass Tort of this size, and it is the part of the story the first page of search results does not reach. The consumer-facing coverage explains what the $5.5 billion buys and repeats the 95% figure. It does not explain what kind of legal object a talc settlement participation threshold actually is, who is empowered to satisfy it, what the court can and cannot do about it, or what happens to a docket of that size if the number comes in at 92%.

What is the 95% participation threshold in the J&J talc settlement?

It is a condition precedent in a private contract. Johnson & Johnson's announcement conditions the entire resolution on the express participation of the lead plaintiff firms in the ovarian talc litigation in state and federal court, representing at least 95% of the remaining claims. Until that condition is satisfied, the agreement does not take effect and nothing is owed. The company put roughly 76,000 claims inside the deal's perimeter and described that as 99.75% of the remaining ovarian claims on file in state and federal court.

Five per cent of about 76,000 is roughly 3,800 claims. Legal Examiner's framing of the arithmetic is the one worth keeping in mind: if firms controlling something on the order of 3,800 claims decline, the deal can fail on its own terms. That is a small fraction of an enormous inventory, and it is why the participation count is now a docket event rather than a private matter between negotiating counsel.

Three features distinguish a talc settlement participation threshold from the settlement mechanics most readers have in mind:

• It is not a Global Settlement in the sense of binding anyone who does not agree. It binds only the claims whose counsel opt in.
• It is not a Class Action settlement. There is no certified class, no Rule 23 finding, no Class Notice, no Objector process and no fairness hearing.
• It is not administered by the court. The court's role right now is to hold the litigation still and require reports.

Who decides whether a talc claim counts toward the participation threshold?

In the first instance, the firm — not the individual claimant. The condition is written in terms of the express participation of lead plaintiff firms on behalf of the claims they represent. A claimant whose case is one of several thousand held by a participating firm is on the participating side of the ledger when that firm signs, and a claimant at a firm that holds out is on the other side, whatever that individual would have chosen.

This is the single most consequential detail in the deal and the one every competing explainer glosses. It converts what looks like a referendum of 76,000 people into a negotiation among a manageable number of inventory holders. It is also what makes the two-week reporting cadence intelligible: the court is not tracking mail-in responses from tens of thousands of households, it is tracking whether a finite set of firms has come across.

Two qualifications matter for practitioners.

First, the firm-level count does not displace the individual client's right to decide. An Aggregate Settlement (Mass Arbitration) or its mass-tort equivalent still runs into the rule that a lawyer may not settle the claims of multiple clients on an aggregated basis without each client's informed consent to the terms and to the disclosure of what every other client is receiving. A firm can commit to participate; it cannot, by that commitment alone, bind a client who refuses the matrix value ultimately offered. The practical effect is a two-stage consent problem: the firm satisfies the threshold, then has to deliver the individual consents underneath it.

Second, the New Jersey state-court side of the litigation has already had its leadership rearranged. A New Jersey appellate ruling in early February 2026 disqualified Beasley Allen from the state talc proceedings on conflict grounds affecting roughly 3,600 state-court cases, and reporting on the federal Plaintiffs' Steering Committee indicates leadership responsibility moved to Ashcraft & Gerel, which was among the firms that negotiated the July 2026 resolution. Who holds the inventory, and who speaks for it, is therefore a live variable rather than a settled fact.

What happens if the talc settlement does not reach 95% participation?

The agreement does not take effect, no money moves, and the litigation resumes where it was paused — which is a considerably worse place for claimants than it was a year ago. The abeyance lifts, the deadlines return, and the question the court had already put to plaintiffs comes back with it.

That question is the show-cause order. On 22 July 2026, five days before the settlement was announced, Magistrate Judge Rukhsanah L. Singh directed ovarian talc plaintiffs to show cause why their remaining claims should not be dismissed for inability to prove Specific Causation. The order followed the withdrawal of plaintiffs' specific-causation experts in bellwether cases — Johnson & Johnson's own filing describes the withdrawal as occurring in two bellwether cases, while Legal Newsline reported that experts were withdrawn as to six plaintiffs selected for the first federal trials, and the discrepancy has not been resolved in public reporting. Either way, the posture is the same: a Daubert Challenge that plaintiffs did not defend, on the element that decides individual cases.

Plaintiffs' response to that order is due 19 November 2026. If the threshold fails, the response becomes the main event, and roughly 69,250 federal actions face a dismissal question with no expert support identified for the causal link between a claimant's talc use and her ovarian cancer. General Causation and Specific Causation are separate hurdles, and it is the second one that the show-cause order targets.

So the downside is asymmetric. A failed threshold does not return the parties to a neutral status quo; it returns them to a docket where the defendant has just demonstrated that the plaintiffs' bellwether experts would not survive scrutiny.

Why the talc settlement participation threshold is 95% and not 80%

Participation thresholds are a standard feature of inventory settlements, and they are normally set where the defendant thinks it can still buy meaningful peace — 85% and 90% are common. A 95% condition is aggressive. It is priced off leverage.

Johnson & Johnson's disclosure to investors characterised the causation development as a watershed, and the sequence supports the characterisation. The withdrawal of specific-causation experts came first, the show-cause order followed on 22 July 2026, and the $5.5 billion proposal was announced on 27 July 2026. A defendant that has just watched the opposing experts leave the field does not need to buy 85% of an inventory; it can insist on near-total closure as the price of paying at all, because its alternative — litigating the show-cause order — has become genuinely attractive.

The same leverage explains the structure. Johnson & Johnson is not capping its aggregate exposure. Reporting on the deal describes a point-based Settlement Matrix that assigns values to qualifying ovarian claims without a ceiling on the total, and Christopher Seeger, who helped negotiate it, has estimated that total payments could exceed $7 billion. A defendant confident in its causation position can afford an uncapped matrix, because it expects the matrix to be applied to fewer, better-documented claims than the raw docket count suggests.

What the deal pays, and what it leaves out

Per-claim values have not been published. The figures circulating on claimant-marketing pages — a range of roughly $100,000 to $1 million, with an average near $500,000 — are legal-industry estimates, not matrix tiers, and no primary source discloses the point values. What is on the record is the perimeter and the cash schedule.

Term	What Johnson & Johnson has stated
Company commitment	$5.5 billion
Claims inside the perimeter	Approximately 76,000 ovarian claims, described as 99.75% of remaining state and federal ovarian claims
Condition precedent	Express participation by lead plaintiff firms representing at least 95% of remaining claims
First payment	No more than $3 billion, in 2027
Further payments	None due before 2028
Aggregate cap	None; claims valued on a point-based Settlement Matrix
Claims excluded	Mesothelioma talc claims; future claims not yet on file
Court approval required	None — this is not a Rule 23 settlement

The two exclusions are load-bearing.

Mesothelioma claims are outside the deal. Those are the asbestos-contamination claims, they are tried in different courtrooms under different proof, and they carry the largest historical verdicts in the talc litigation. Resolving the ovarian inventory does not retire that exposure.

Future claims are also outside it. This is the structural difference between a negotiated inventory resolution and the bankruptcy route Johnson & Johnson tried three times. A confirmed plan with a channelling injunction — the Section 524(g) Trust model built for asbestos — is designed precisely to capture claimants who have not yet been diagnosed. A settlement negotiated in the tort system cannot do that. Whatever the participation count reaches, the company remains exposed to the next claimant who files.

Why Johnson & Johnson is doing this outside bankruptcy

Because the bankruptcy route failed three times, and the third failure closed it.

The company's approach from 2021 onward used a Texas Two-Step: a divisional merger under Texas law placing talc liabilities in a newly created subsidiary, which then filed for Chapter 11 in the hope of resolving the entire liability — present and future — through a trust and a channelling injunction. The Third Circuit dismissed the first attempt for lack of financial distress. A second filing followed and failed. The third, Red River Talc LLC, proposed a fund reported at roughly $9 billion; on 31 March 2025, Judge Christopher Lopez of the Bankruptcy Court for the Southern District of Texas denied confirmation of the prepackaged plan and dismissed the case for cause, citing voting irregularities and impermissible third-party releases. Johnson & Johnson said it would return to the tort system rather than appeal.

Attempt	Vehicle	Outcome	Date
First	LTL Management Chapter 11 after divisional merger	Dismissed for lack of financial distress	2023
Second	Refiled LTL Chapter 11	Dismissed	2023
Third	Red River Talc LLC prepackaged plan, reported ~$9 billion	Confirmation denied, case dismissed for cause	31 March 2025
Fourth	Negotiated inventory settlement, $5.5 billion, 95% participation condition	Pending; participation reported to the MDL court every two weeks from 15 September 2026	2026

The fourth attempt is the first one that requires the plaintiffs' side to say yes. That is the whole significance of the talc settlement participation threshold: having lost the ability to impose finality through a bankruptcy court, Johnson & Johnson has to purchase it firm by firm, and it has set the purchase price at near-unanimity.

Why this is not a class settlement, and why that matters

Readers who follow consumer class practice will reach for the wrong mental model here. In a Rule 23 settlement, a court certifies a Settlement Class, approves notice, holds a fairness hearing, rules on objections, fixes fees, and enters a judgment that binds absent members who did not opt out. None of that exists in MDL 2738.

An MDL is a pretrial coordination device under 28 U.S.C. § 1407, not an aggregation of substantive rights. The Judicial Panel on Multidistrict Litigation (JPML) transfers cases for common pretrial proceedings; each case remains its own case. When an inventory settlement resolves an MDL, what actually happens is thousands of individual settlements executed in parallel, papered by counsel, and funded through a Qualified Settlement Fund (QSF) administered by a Claims Administrator, frequently with a Special Master supervising allocation and lien resolution.

Three practical consequences follow, and none of the top-ranking pages on this story state them:

1. No judge will find this settlement fair, reasonable and adequate, because no judge is asked to. The court's supervisory role is the abeyance order and the reporting requirement.
2. There is no court-administered opt-out. A claimant who does not want the matrix value does not file an exclusion form with a claims administrator; the claimant declines to sign the release and continues litigating an individual case, with the show-cause order waiting.
3. Objectors have no forum. A claimant who believes the matrix undervalues her claim relative to others has an ethics complaint and a malpractice theory, not a hearing date.

This is the same reason the two-week reports matter. In a Rule 23 case, participation is a matter of public record by operation of the notice process. Here, the only visibility anyone outside the negotiation has into whether the talc settlement participation threshold is being met is a status report filed with the court.

The mass arbitration parallel: this is a blow-up provision

Practitioners who work on aggregated arbitration will recognise the architecture immediately, because it is the same architecture.

A Blow-Up Provision in an Aggregate Settlement (Mass Arbitration) lets a respondent walk away if fewer than a stated percentage of claimants accept the deal. It exists for the same reason the 95% condition exists: a respondent paying to end a coordinated inventory is buying peace, not claims, and peace that leaves 10% of the inventory in the field is worth far less than the arithmetic suggests, because the residue is self-selecting for the strongest cases and the most aggressive Coordinated Counsel.

The mass arbitration version usually carries machinery the talc deal appears to lack in public form: a stated walk-away percentage, a defined acceptance window, a mechanism for the respondent to waive the condition if the count comes in close, and sometimes a sliding scale that reduces the fund rather than voiding the deal. Johnson & Johnson's public description states the percentage and nothing else. Whether the underlying agreement contains a waiver right, a cure period or a reduced-fund fallback is not on the record, and the absence of that detail is exactly what makes the reporting cadence consequential: an outside observer learns the state of the condition only when Negotiation Counsel files.

The comparison runs the other way as well. Mass arbitration respondents adopted blow-up provisions because they learned that paying a partial inventory funds the next campaign. Johnson & Johnson is applying the same lesson to a Mass Tort docket — with the added wrinkle that, because the deal does not cover future claims, even a 100% participation count does not end the litigation. It clears the shelf. It does not close the store.

What the two-week reports on the talc settlement participation threshold will and will not show

The reporting requirement is narrow, and reading too much into it would be a mistake. The court found good cause to require regular updates as to the status of communications with claimants, claimant participation and the settlement process. That is a description of three topics, not a disclosure schedule.

What a report of that kind can reasonably be expected to convey is direction of travel: whether Negotiation Counsel are still engaged with the firms that have not signed, whether claimant outreach is underway, and whether the parties think the condition remains reachable. What it is unlikely to convey is a precise running percentage, firm-by-firm attribution, or the terms on which any particular inventory came across. Settlement communications are ordinarily protected, and negotiating counsel have an obvious interest in not publishing a number that tells holdout firms exactly how much leverage they are holding.

That last point deserves emphasis, because it is a genuine tension in the design. A participation threshold creates a holdout premium: the closer the count gets to 95%, the more each remaining claim is worth to the defendant, and the stronger the incentive to sit out and negotiate separately. Publishing an accurate running total every fortnight would sharpen that incentive rather than blunt it. A count that becomes fully transparent at 93% is a count that may never reach 95%.

The corollary is that the absence of a reported percentage is not evidence of trouble. As of this week, no public source has reported a participation figure of any kind, and none should be expected to until either the condition is satisfied, the parties ask the court to lift the abeyance, or someone walks away.

What practitioners can watch instead is the docket's shape. Three signals would be more informative than any interim number: an order extending or modifying the abeyance, which implies the parties want more time; a motion touching the 19 November 2026 show-cause response, which implies they are preparing for the deal to fail; and any movement on the bellwether track, which has been dormant since the specific-causation experts were withdrawn. A quiet docket punctuated by fortnightly reports means the negotiation is proceeding. Activity on the show-cause response means it is not.

Timeline: from the causation ruling to the participation clock

Date	Event
31 March 2025	Red River Talc plan confirmation denied; case dismissed for cause; Johnson & Johnson says it will return to the tort system
7 February 2026	New Jersey appellate ruling disqualifies Beasley Allen from the state talc proceedings, affecting roughly 3,600 state-court cases
Mid-2026	Plaintiffs withdraw specific-causation experts in bellwether cases after a reliability hearing
22 July 2026	Magistrate Judge Rukhsanah L. Singh orders plaintiffs to show cause why remaining claims should not be dismissed for failure of Specific Causation
27 July 2026	Johnson & Johnson announces a $5.5 billion proposed resolution conditioned on 95% participation
3 August 2026	JPML report counts 68,914 pending actions in MDL No. 2738
1 September 2026	Federal count rises to 69,250 pending actions, the largest active MDL
15 September 2026	First biweekly Negotiation Counsel report on claimant communications, claimant participation and the settlement process
Every two weeks thereafter	Further participation reports, until otherwise ordered
19 November 2026	Plaintiffs' response to the show-cause order due
2027	First settlement payment of no more than $3 billion, if the condition is satisfied
2028	Earliest date for any further payment

What it means for claimants and their counsel

For an individual claimant, the decision that matters is not whether to "join a settlement" — it is whether to accept a matrix value that has not yet been disclosed, from a firm that has already committed at the inventory level. Claimants should expect the sequence to be: firm participates, threshold is reported, matrix values are communicated, individual consents are collected. A claimant who intends to hold out is holding out against the 19 November 2026 show-cause deadline, not against a fairness hearing.

For claimants' firms, the exposure is the gap between the firm-level commitment and the client-by-client consent underneath it. The aggregate-settlement rule does not bend because the inventory is large. A firm that reports participation it cannot deliver in individual consents has created a problem for the count and for itself.

Holding out also carries a calendar risk that has nothing to do with the merits. Claims that have sat on an MDL docket for years under a Tolling Agreement or a direct-filing order depend on those arrangements continuing; a claimant who leaves the settlement track and the coordinated docket at the same time needs to know exactly which Statute of Limitations applies to her case in her home jurisdiction and what, if anything, has been tolling it. That is a file-by-file question, and it is not answered by the participation count.

For firms holding small inventories, the arithmetic is worth doing deliberately. At roughly 3,800 claims, the 5% tolerance is thin enough that a handful of mid-sized holdouts is decisive — which gives small holders more leverage than their share of the docket implies, and also makes them the obvious targets of side negotiation.

What it means for defense counsel, funders and lienholders

For defense counsel, the case study is the sequencing. Johnson & Johnson did not offer near-unanimity pricing until after the causation record turned. The order of operations — press the reliability challenge, let the experts withdraw, obtain the show-cause order, then propose terms — is the reason a 95% condition was credible rather than laughable. It is also a reminder that a Daubert Challenge in an MDL is a settlement instrument as much as an evidentiary one.

For Third-Party Litigation Funding, a conditional settlement is a duration problem. A funder underwriting talc claims priced a return against an expected resolution date; that date is now contingent on a count reported fortnightly, with a failure scenario that sends the portfolio back to a dismissal motion rather than to trial. Funders holding positions across multiple claimant firms also sit on both sides of the threshold, since a portfolio's value depends on whether other firms participate.

For lienholders and their counsel, nothing is payable and nothing is negotiable until the condition is satisfied. Medical Lien resolution, Medicare and Medicaid reimbursement and any hospital or provider liens all queue behind a QSF that does not exist yet. Lien resolution vendors working this inventory are in the same posture as everyone else: waiting on a number in a status report.

For the court, the abeyance order is a reasonable use of docket control and also an acknowledgement of its limits. A transferee judge cannot make firms sign. What the judge can do is stop the clock on 69,250 cases so that the negotiation is not overtaken by deadlines, and require that the parties say, on the record and on a schedule, whether it is working.

Frequently asked questions

What is the 95% participation threshold in the J&J talc settlement?

It is a contractual condition requiring that lead plaintiff firms representing at least 95% of the remaining ovarian talc claims expressly participate before Johnson & Johnson's $5.5 billion commitment takes effect. Until the condition is met, the agreement is not operative and no payment obligation arises.

What happens if the talc settlement does not reach 95% participation?

The agreement does not take effect and the litigation resumes. The abeyance in MDL No. 2738 lifts, and plaintiffs face the 22 July 2026 show-cause order requiring them to explain why their claims should not be dismissed for failure of Specific Causation, with a response due 19 November 2026.

Who decides whether a talc claim counts toward the participation threshold?

The claimant's law firm, in the first instance. The condition is framed in terms of lead plaintiff firms' express participation on behalf of the claims they represent. The individual claimant still has to consent to any specific settlement amount, because the aggregate-settlement rule requires informed individual consent before a lawyer resolves multiple clients' claims together.

How much will the J&J talc settlement pay per claim?

Per-claim values have not been published. The deal is reported to use a point-based Settlement Matrix that assigns values to qualifying ovarian claims without capping Johnson & Johnson's aggregate payment, and Christopher Seeger has estimated total payments could exceed $7 billion. Ranges circulating online — commonly $100,000 to $1 million — are industry estimates, not disclosed matrix tiers.

Does the $5.5 billion talc settlement cover mesothelioma claims?

No. The resolution addresses ovarian cancer talc claims. Mesothelioma talc claims are outside it, as are claims not yet on file, so Johnson & Johnson retains exposure on both fronts regardless of the participation count.

When will talc settlement payments start?

If the condition is satisfied, Johnson & Johnson has said the first payment will be no more than $3 billion in 2027, with no further payments due before 2028. Actual distribution to claimants would follow claims processing and lien resolution through a Qualified Settlement Fund (QSF), not the funding date.

What is the current status of MDL 2738?

Deadlines are held in abeyance while Negotiation Counsel file biweekly reports on claimant communications, claimant participation and the settlement process, the first of which was due 15 September 2026. The docket held 69,250 pending actions as of 1 September 2026, and no participation percentage has been reported publicly.